PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26629687-3	2015	OBJECTIVE: To assess an alternative therapeutic approach to systemic administration of brain-derived GM1 to enhance GM1 levels in the brain via enzymatic conversion of polysialogangliosides into GM1 and to assess the neuroprotective potential of this approach.	trisialoganglioside GT1	168-189	coenzyme Q10A	Mus musculus	101-104	
1443421-4	1992	Hydrolysis of the polysialogangliosides by neuraminidase to the end-product, GM1, at early time periods occurred more rapidly in LS than in SS synaptosomes.	trisialoganglioside GT1	18-39	coenzyme Q10A	Mus musculus	77-80	
6363631-9	1983	The induced receptors, as well as their precursors, were resistant to trypsin and proteinase K. We conclude that the internodal Schwann cell surface is rich in an unidentified polysialoganglioside(s) that can be converted to GM1 by neuraminidase.	trisialoganglioside GT1	176-196	coenzyme Q10A	Mus musculus	225-228	
9143118-9	1997	The purified enzyme hydrolyzed polysialogangliosides to produce GM1 but did not act on GM1.	trisialoganglioside GT1	31-52	coenzyme Q10A	Mus musculus	64-67	
9143118-10	1997	It was therefore concluded that polysialogangliosides in the culture of strain YF-2 were converted to GM1 by this sialidase.	trisialoganglioside GT1	32-53	coenzyme Q10A	Mus musculus	102-105	
26629687-3	2015	OBJECTIVE: To assess an alternative therapeutic approach to systemic administration of brain-derived GM1 to enhance GM1 levels in the brain via enzymatic conversion of polysialogangliosides into GM1 and to assess the neuroprotective potential of this approach.	trisialoganglioside GT1	168-189	coenzyme Q10A	Mus musculus	116-119	
26629687-3	2015	OBJECTIVE: To assess an alternative therapeutic approach to systemic administration of brain-derived GM1 to enhance GM1 levels in the brain via enzymatic conversion of polysialogangliosides into GM1 and to assess the neuroprotective potential of this approach.	trisialoganglioside GT1	168-189	coenzyme Q10A	Mus musculus	116-119	
26629687-9	2015	CONCLUSION: The results suggest that enzymatic conversion of polysialogangliosides to GM1 may be a viable treatment strategy for increasing GM1 levels in the brain and exerting a neuroprotective effect on the damaged nigrostriatal DA system.	trisialoganglioside GT1	61-82	coenzyme Q10A	Mus musculus	86-89	
26629687-9	2015	CONCLUSION: The results suggest that enzymatic conversion of polysialogangliosides to GM1 may be a viable treatment strategy for increasing GM1 levels in the brain and exerting a neuroprotective effect on the damaged nigrostriatal DA system.	trisialoganglioside GT1	61-82	coenzyme Q10A	Mus musculus	140-143